Patent and Regulatory approvals

iCIP™ has strong new patent protection until 2038.

The LiPlaCis drug response predictor – DRP® (an in vitro diagnostic medical device (IVD)) has a CE-marking that enables commercialization in 32 European countries.

LiPlaCis has a 505(b)2 from the US Food & Drug Administration (FDA) which allows reduced development time. In addition, the FDA has approved an IDE (Investigational Device Exemption) application for use of the company’s drug response predictor LiPlaCis DRP® in clinical studies.